Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007
October 25 2007 - 8:30AM
PR Newswire (US)
WELLESLEY, Mass., Oct. 25 /PRNewswire-FirstCall/ -- Coley
Pharmaceutical Group, Inc. (NASDAQ:COLY), today announced that the
company will host an investor conference call at 4:30 p.m. Eastern
Time on November 1, 2007 to discuss second quarter 2007 financial
results. To access the live audio broadcast or the subsequent
archived recording of the call, please visit the Investor Center
section of the Coley website at http://www.coleypharma.com/. Please
log onto Coley's website several minutes prior to the start of the
call to ensure adequate time for any software download that may be
required. A replay of this webcast will be available through
November 15, 2007. Investors may participate in the conference call
by dialing either + 1- 888-713-4217 in the U.S. or + 1-617-213-4869
outside the U.S. and typing in the passcode 20929767. A replay of
this call will be available at + 1-888- 286-8010 (U.S.) or +1-
617-801-6888 (international) using the passcode 82770375 until
November 15, 2007. The webcast is also being distributed through
the Thomson StreetEvents Network to both institutional and
individual investors. Individual investors can listen to the call
at http://www.fulldisclosure.com/ and institutional investors can
access the call via http://www.streetevents.com/. About Coley
Pharmaceutical Group Coley Pharmaceutical Group, Inc. is an
international biopharmaceutical company, headquartered in
Wellesley, Massachusetts, USA, that discovers and develops TLR
Therapeutics(TM), a new class of investigational drug candidates
that direct the human immune system to fight cancers, allergy and
asthma disorders and to enhance the effectiveness of vaccines.
Coley has established a pipeline of TLR Therapeutic product
candidates currently advancing through clinical development with
partners and has additional product candidates in preclinical
development. Coley has product development, research and license
agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck,
Novartis Vaccines and the United States government. For further
information on Coley Pharmaceutical Group please visit
http://www.coleypharma.com/. Safe Harbor Statement Certain
statements in this news release concerning Coley's business are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be
wrong. They can be affected by inaccurate assumptions Coley might
make or by known or unknown risks and uncertainties, including, but
not limited to: the early stage of product development;
uncertainties as to the future success of ongoing and planned
clinical trials; the risk that results from early stage clinical
trials may not be indicative of results in later stage trials; the
unproven safety and efficacy of products under development;
intellectual property rights and litigation; competitive products;
and other risks identified in Coley's filings with the Securities
and Exchange Commission including, but not limited to, Coley's
Annual Report on Form 10-K for the fiscal year ended December 31,
2006. Consequently, no forward-looking statement can be guaranteed,
and actual results may vary materially. Coley undertakes no
obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise, except as
required by applicable law. DATASOURCE: Coley Pharmaceutical Group,
Inc. CONTACT: Susan Hager, Sr. Director, Investor Relations and
Corporate Communications of Coley Pharmaceutical Group, Inc.,
+1-781-431-9079, ; Media, Karen L. Bergman, +1-650-575-1509, , or
Michelle Corral, +1-415-794-8662, , both of BCC Partners for Coley
Pharmaceutical Group, Inc. Web site: http://www.coleypharma.com/
Copyright
Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Historical Stock Chart
From Apr 2024 to May 2024
Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Historical Stock Chart
From May 2023 to May 2024